Ambitious plans for treatment as prevention in Asia, but challenges remain
Dolutegravir superior to raltegravir for treatment-experienced people with HIV
Reduced efavirenz dose suppresses HIV as well as standard dose
Study supports WHO recommendations for second-line HIV therapy in resource-limited countries
Bangkok PrEP study finds PrEP efficacy is related to drug exposure
PrEP appears safe for use in conception, but may not be necessary if partner is taking treatment
First-ever community-randomised combination prevention trial produces modest drop in HIV incidence, big increase in testing in men
Two stem cell transplant recipients now controlling HIV off treatment
How can most-at-risk populations be encouraged to seek HIV testing?
